表皮生长因子受体靶向RNAi抑制恶性肿瘤中的研究现状  

The research status quo of RNA interference gene therapy targeting the human epidermal growth factor receptor in the malignant neoplasm

作　　者：滕帼英[1] 潘泽政[1] 吴剑[1] 毛位贞[1] 

机构地区：[1]江西医学院上饶分院生化教研室,江西上饶334000

出　　处：《井冈山医专学报》2008年第6期14-16,共3页Journal of Jinggangshan Medical College

摘　　要：表皮生长因子受体(EGFR)在许多恶性肿瘤中有过度表达或突变的现象,它借助信号转导使细胞的生长失控和恶化,与肿瘤的发生、发展、转移及预后等密切相关。因此,抑制内源性EGFR及其突变体的表达,是有效治疗恶性肿瘤的途径之一。RNAi是一种发展迅速且极有应用前景的基因治疗技术,细胞内存在一个完整的可引发RNA干扰结构,可将EGFR外源性双链RNA裂解成21～23个核苷酸短干扰RNA(SiRNA),后者可自动杂交同源EGFR的mRNA上并使之降解,从而达到抑制EGFR表达和治疗恶性肿瘤的目的。The epidermal growth factor receptor （EGFR） mutations have usually occurred in malignant tumor, which will make the growth of the cellular out of control and depravation through the signal transductions pathway, so the EGFR mutations were closely related to the occurrence, development and transformation of tumors. Therefore, inhibition the expression and mutation of EGFR may be an effective treatment for malignant neoplasm, RNAi is a new genetic treatment technique, which developed rapidly and had broad application foreground. There are a RNA interference fabric in the cell, it can triggers the degradation of the extrinsic duplex RNA of EGFR to 21-23 SiRNA, then the 21-23 SiRNA trigger restraining the expression of EGFR.

关 键 词：卡基因治疗 表皮生长因子受体EGFR RNAI 恶性肿瘤 

分 类 号：R730.54[医药卫生—肿瘤]